- In a 24-month 956-patient Phase 3 clinical trial, Pfizer's (PFE) rheumatoid arthritis (RA) drug Xeljanz demonstrated superior results over methotrexate in patients who had not previously taken methotrexate.
- Xeljanz achieved its primary endpoint of statistically significantly superior results in inhibiting the progression of structural damage and reducing the signs and symptoms of RA compared to methotrexate at month six in patients with moderate-to-severe disease. The recommended dose is a 5 mg pill BID.
- Xeljanz is a Janus-associated kinase (JAK) inhibitor that helps reduce RA symptoms such as joint pain, swelling and stiffness. It works by disrupting the signaling of cytokines related to the inflammation of RA.
- The study results have just been published in the New England Journal of Medicine.
From other sites
at CNBC.com (Apr 10, 2015)
at Zacks.com (Apr 8, 2015)
at Zacks.com (Apr 7, 2015)
at Investopedia (Apr 7, 2015)
at MarketRealist.com (Mar 27, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs